KRAS and ovarian serous adenocarcinoma: High-grade serous ovarian adenocarcinomas have prevalent TP53 mutations; mucinous ovarian cancer tumors have frequent KRAS mutations; and clear cell ovarian cancer and endometrioid ovarian cancer tumors have a lower rate of TP53 and frequent ARID1A and PIK3CA mutations8.